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Proof of concept: used malaria rapid 
diagnostic tests applied for parallel 
sequencing for surveillance of molecular 
markers of anti-malarial resistance in Bissau, 
Guinea-Bissau during 2014–2017
Sidsel Nag1,2* , Johan Ursing3,4,5, Amabelia Rodrigues5, Marina Crespo1,2, Camilla Krogsgaard1,2, Ole Lund6, 
Frank M. Aarestrup7, Michael Alifrangis1,2 and PouL‑Erik Kofoed5,8*
Abstract 
Background: Large‑scale surveillance of molecular markers of anti‑malarial drug resistance is an attractive method 
of resistance monitoring, to complement therapeutic efficacy studies in settings where the latter are logistically 
challenging.
Methods: Between 2014 and 2017, this study sampled malaria rapid diagnostic tests (RDTs), used in routine clinical 
care, from two health centres in Bissau, Guinea‑Bissau. In order to obtain epidemiological insights, RDTs were col‑
lected together with patient data on age and sex. A subset of positive RDTs from one of the two sites (n = 2184) were 
tested for Plasmodium DNA content. Those testing positive for Plasmodium DNA by PCR (n = 1390) were used for 
library preparation, custom designed dual indexing and next generation Miseq targeted sequencing of Plasmodium 
falciparum genes pfcrt, pfmdr1, pfdhfr, pfdhps and pfk13.
Results: The study found a high frequency of the pfmdr1 codon 86N at 88–97%, a significant decrease of the pfcrt 
wildtype CVMNK haplotype and elevated levels of the pfdhfr/pfdhps quadruple mutant ranging from 33 to 51% 
between 2014 and 2017. No polymorphisms indicating artemisinin tolerance were discovered. The demographic 
data indicate a large proportion of young adults (66%, interquartile range 11–28 years) presenting with P. falcipa-
rum infections. While a total of 5532 gene fragments were successfully analysed on a single Illumina Miseq flow cell, 
PCR‑positivity from the library preparation varied considerably from 13 to 87% for different amplicons. Furthermore, 
pre‑screening of samples for Plasmodium DNA content proved necessary prior to library preparation.
Conclusions: This study serves as a proof of concept for using leftover clinical material (used RDTs) for large‑scale 
molecular surveillance, encompassing the inherent complications regarding to methodology and analysis when 
doing so. Factors such as RDT storage prior to DNA extraction and parasitaemia of the infection are likely to have an 
effect on whether or not parasite DNA can be successfully analysed, and are considered part of the reason the data 
yield is suboptimal. However, given the necessity of molecular surveillance of anti‑malarial resistance in settings 
where poor infrastructure, poor economy, lack of educated staff and even surges of political instability remain major 
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Background
In anticipation of novel emergence or geographic 
spread of especially artemisinin-resistant Plasmodium 
falciparum parasites [1–3], countries with malaria 
transmission are recommended by the World Health 
Organization (WHO), to test the efficacy of their rec-
ommended artemisinin-based combination therapy 
(ACT) every 2–3  years [4]. Therapeutic efficacy stud-
ies are often not feasible due to economic and practi-
cal constraints in many settings in sub-Saharan Africa 
(SSA). It has therefore been suggested that molecu-
lar surveillance of genetic polymorphisms associated 
with anti-malarial resistance [4–9] could complement 
therapeutic efficacy studies because these can provide 
early warning signs of decreasing anti-malarial efficacy 
[10]. Molecular surveillance only requires sampling 
of P. falciparum infected blood, which in turn can be 
acquired from finger prick samples. Malaria rapid diag-
nostic tests (RDTs), which are routinely used in clinical 
care in SSA, represent a massive body of finger prick 
blood samples, readily acquirable across SSA. Their 
use for molecular analyses is well described [11–13], 
but large-scale analyses using reliable, high through-
put methodologies remains to be seen. Meanwhile, 
high throughput molecular analysis has become reli-
able and affordable with novel protocols based on next 
generation sequencing (NGS) technology [14–16]. If 
large-scale, high throughput molecular analysis of anti-
malarial resistance markers is feasible on used RDTs, 
large-scale molecular surveillance of anti-malarial 
resistance can become reality.
The current study was carried out in the capital of 
Guinea-Bissau. Malaria epidemiology in Guinea-Bissau 
has changed during the past decades and is now highly 
seasonal with epidemics occurring from September, 
peaking in November and lasting through January [17, 
18]. Children aged < 5 years no longer account for the 
majority of malaria cases as the median age is gradu-
ally increasing [18]. Since 2008, the first-line treatment 
for malaria has been artemether–lumefantrine (AL) 
[19], which was shown to be effective in the Bissau 
area [20]. Quinine (QN) is the second- and third-line 
treatment for malaria [19] and is, therefore, also used 
occasionally. Intermittent preventive treatment in preg-
nancy (IPTp), with sulfadoxine-pyrimethamine (SP), 
is implemented [19]. Lastly, during the study period 
dyhydroartemisinin–piperaquine (DP) was is in clinical 
trial being compared to AL for treatment of children.
The primary objective of this study was to evaluate 
whether used RDTs, collected after routine use in clini-
cal care, can serve as source of parasite DNA for large-
scale NGS-based molecular surveillance of anti-malarial 
resistance. Based on the hypothesis that parasite DNA 
can be extracted from used RDTs, a modified version of 
a previously published NGS-based amplicon sequenc-
ing methodology was used [15]. The molecular approach 
investigated to what extent SNPs and genes associated 
with tolerance/resistance towards the majority of cur-
rently available anti-malarial treatments could be ana-
lysed in this high-throughput manner, applying massive 
parallel sequencing and a custom-made sample-indexing 
approach. A secondary objective was to provide tem-
poral molecular marker data from the setting in Bis-
sau, Guinea-Bissau, based on the successful application 
of used RDTs for molecular surveillance. Samples were 
obtained from May 2014 until April 2017 together with 
minimal patient information in order to provide a basic 
description of the demographic trends amongst malaria 
patients versus non-malaria patients in the study area.
Methods
RDT sampling
Positive and negative RDTs were collected from patients 
of all ages whom health workers suspected might be 
infected with P. falciparum (typically associated with 
presence of a fever within the last 24  h), presenting at 
the Bandim or Belem health centres from May 2014 until 
April 2017. Patient age, sex and date of collection were 
written on the RDT and on a clinical records form. All 
information was put into a folder on a daily basis, and 
subsequently entered into an electronic database. RDTs 
were collected in a storage box containing silica gel, 
which was kept dark at room temperature (20–35  °C), 
and stored between 3 and 9  months before shipment 
to Denmark, where they were stored between 0 and 
9  months at room temperature before DNA extraction 
was performed.
Study size
The study size varies throughout the study, with 
decreasing study size as the study progresses, because 
samples fail to meet the developing study criteria. 
obstacles to performing clinical studies, obtaining the necessary data from used RDTs, despite suboptimal output, 
becomes a feasible, affordable and hence a justifiable method.
Keywords: Plasmodium falciparum, Guinea‑Bissau, Molecular markers of antimalarial resistance, Rapid diagnostic 
tests, Next‑generation sequencing, Amplicon sequencing, pfcrt, pfmdr1, pfdhfr, pfdhps, pfk13
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Please view Fig.  1 for a visualization of the following: 
The initial study size was based on RDTs collected at 
the study sites, which were included in the database 
received in Denmark. RDTs were collected based on 
the criteria listed above (RDT sampling). The included 
samples were then categorized according to whether 
samples were positive or negative at the time of diag-
nosis (and hence listed as such in the database). Sub-
sequently, the study size is massively reduced, as DNA 
is only extracted from a small subset of the negative 
RDTs. Furthermore, although DNA was intended 
extracted from all of the positive RDTs, as subset was 
lost due to faulty extraction. The cause for the faulty 
extraction was never identified, however no DNA 
was acquired from the tests extracted during a spe-
cific batch. Furthermore, the identification number, as 
well as patient data visible on the extracted RDTs was 
double checked with that from the database, at which 
point, samples not identified in both were discarded. At 
this point, the study size for estimating successful DNA 
extraction from positive RDTs/false-negative RDTs was 
derived. The study size for the molecular analysis was 
based on the RDTs from which DNA was successfully 
extracted.
DNA extraction
DNA was extracted by the chelex method, as described 
previously [21], in a 96-well format with no samples in 
lane 12 and 4 blanks dispersed between lanes 1 and 11.
PCR‑corrected RDT positivity and negativity
A PCR amplifying the multicopy ribosomal 18S subunit 
of all Plasmodium species was performed on all positive 
RDTs received in Denmark, as well as on 304 negative 
RDTs from the high transmission seasons of 2014 and 
2015. The PCR protocol has been described previously 
[22].
Genetic analysis
Molecular markers of anti-malarial resistance were 
assessed by NGS-based amplicon sequencing, using a 
modified version of a previously published protocol [15]. 
In brief, amplicons (amplified gene-fragments) from the 
infecting parasites, depicted in Fig.  2, were produced 
Fig. 1 Sample screening and processing. Samples were collected from all patients tested with an RDT, and subsets of positive and negative 
samples were used for DNA extraction and subsequent analyses. *Almost all samples from Belem were lost due to faulty extraction procedures, 
and other samples logged in the database were never identified amongst the RDTs received. #A number of positive RDTs received in Denmark, 
were not found in the database (no RDT with corresponding number or information had been logged). DNA extraction was performed before 
cross‑referencing samples with the electronic database because the electronic database was not ready when samples were received, and 
postponing DNA‑extraction was avoided
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by PCR and prepared for massively parallel sequencing 
on the Illumina Miseq sequencer through a previously 
published PCR-based library-preparation method [15] 
(based on Illumina’s own protocol for 16S metagenom-
ics sequencing [23]). Primers synthesized for the previ-
ously published study, as well as some newly synthesized 
primers were used (see section regarding “Library prepa-
ration”). All amplicons pertaining to the same infection 
were barcoded with the same unique set of custom-made 
indices in the 5′ and 3′ ends. All barcoded amplicons 
were pooled prior to sequencing and sequenced in par-
allel. De-multiplexing of sequence data was performed 
based on all of the unique index-combinations given to 
the samples during library preparation. The original mul-
tiplex, non-nested amplification of gene-fragments were 
modified to simplex, nested amplification of the same or 
slightly modified gene-fragments (Fig. 2) due to the min-
ute amount of DNA contained in RDT extracts [15]. As 
all PCRs were performed in simplex, certain fragments 
were redesigned to accommodate all of the genetic posi-
tions of interest within a single fragment (to reduce the 
number of PCRs), instead of two fragments (regard-
ing pfdhps and 3′-pfmdr1). In these cases, certain areas 
of the fragments are not sequenced, as the paired-end 
300  bp sequencing is not long enough to sequence the 
entire fragment. All primers are listed in Additional file 1: 
Table S1.
Controls and duplicates
The majority of samples were run once, with 10% of 
samples run as duplicates. Control samples used in the 
study consisted of DNA from well characterized para-
site-lines (viable in culture), namely 3D7, FCR3, DD2, 
K1, 7G8, MRA-1238 and MRA-1239 [9], the latter two 
of which are pfk13 controls. Other controls consisted 
of patient samples from earlier studies, where the hap-
lotypes within specific genes are known, namely AA 
(pfdhps 436A + 437A), AG (pfdhps 436A + 437G), 540E 
(pfdhps 540E) and 164L (pfdhfr 164L). An entire overview 
of control sample haplotypes is listed in Additional file 1: 
Table S2.
Library preparation
A series of optimization attempts were performed to 
increase the PCR-positivity rate for the amplicons incor-
porated in the library. These attempts included (1) going 
from multiplex to simplex PCRs, (2) gradients on anneal-
ing temperatures (3) two-step annealing with an initial 
Fig. 2 Amplicons incorporated in the sequencing library preparation. Fragments from pfcrt, pfmdr1, pfdhfr, pfdhps and pfk13 were incorporated 
in the sequencing library. Grey circles indicate SNP positions of interest, and the numbering corresponds to codons. Grey lines indicate areas of 
amplicons that are not sequenced
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annealing of 40–44 °C for 5 cycles followed by annealing 
of 55–60 °C for 20–35 cycles, (4) increased cycle number 
during annealing (5) increased annealing and extension 
times and finally (6) altered primer sites. The optimiza-
tions were performed on all of the individual amplicons, 
with little to no effect. In conclusion,
PCRs were performed as described previously [15], 
with the following alterations: all fragments were ampli-
fied individually, and as nested PCRs, requiring new 
primer design for some of the primers. The outer and the 
nested PCR programs were identical to the previously 
published “gene-specific PCR”, except that they consisted 
of 40 cycles each. The nested PCR was performed with 
primers containing the overhangs, as was previously the 
case for the “gene-specific PCR”. The nested PCR prod-
ucts were pooled according to sample of origin, prior to 
index PCR, as described previously. The index PCR was 
run according to the original protocol [15]. All prim-
ers and corresponding fragments are listed in Addi-
tional file 1: Table S1, and depicted in Fig. 2. Fragments 
included in the study cover pfcrt codon (c) c. 31–138, 
pfmdr1 c. 60-237 and c. 1022-1260 (where c. 1123-1160 
are not sequenced), pfdhfr c. 12-174, pfdhps c. 392-622 
(where c. 492-522 are not sequenced) as well as pfK13 c. 
17-709.
Amplicon purification, dilution, pooling and sequenc-
ing were all performed as previously described, at the 
DTU Multi Assay Core (DMAC), Technical University of 
Denmark [15].
Quality trimming and base calling
Data was demultiplexed by the sequencer, using a cus-
tom-sample sheet (the amount of samples analysed in 
this study cannot be demultiplexed by BaseSpace, the run 
is visualized as faulty). Quality trimming of raw sequenc-
ing reads was performed using cutadapt [24], removing 
the 5′-primer sequence of every read, and setting a qual-
ity cut-off of 20. Data analysis was performed with assim-
pler [25], as described previously [15]. Briefly: assimpler 
is a python program which compares reads to a custom 
database. The program was set to call bases with a mini-
mum z-score of 1.96.
Mixed infections
Infections were defined as mixed if more than one base 
was called for a given position in a given sample, and was 
supported by at least 25% of the calls for that position 
for the sample in question. A minimum of 25% of calls 
was set as threshold, because a certain amount of calls is 
required to support the given base call. With the amount 
of samples simultaneously sequences on the flow cell, 
there will be variation in the amount of calls per position 
per sample.
Statistics
Pearson’s Chi square was used to assess whether there 
was a difference in the proportions of children and adults 
amongst RDT-positive patients as compared to the gen-
eral population. Fisher’s exact test was used to assess 
whether there was a significant trend over time in the 
frequencies of the detected haplotypes. Mixed infections 
were counted in all groups for single SNP-prevalence and 
omitted for haplotypes.
Bias
Two main elements represent theoretical bias in this 
study. However, they have either been discussed as bias 
in “Discussion” section or addressed in the methodology.
1. Bias within the sample population: All samples were 
acquired at a health care centre and samples are 
assumed to be derived from symptomatic patients. 
This introduces a demographic bias, as some demo-
graphic groups are less likely to experience symp-
toms (elderly people with high acquired immunity 
and adults in general with very low-parasitaemic 
infections).
2. Bias within the gene sequences: In order to success-
fully analyse the genetic sequence of the genes of 
interest to anti-malarial resistance, specific primers 
have been designed to amplify the genes of inter-
est. First of all, if there is genetic variation within 
the primer sequence, the gene is either not amplified 
for the specific sample, or the genetic variation will 
not be identified if successfully amplified. The latter 
is due to the primer sequence being trimmed from 
the sequences analysed, in order to not introduce 
primer-bias.
Results
Evaluation of the applicability of RDTs as source of DNA 
for NGS‑based molecular surveillance
PCR‑corrected RDT positivity and negativity
In total, 14,933 RDTs were used to diagnose patients at 
the two health centres between May 2014 and April 2017, 
and collected. Out of these, 2832 RDTs were positive. A 
flow chart depicting the sample screening and selection 
process is shown in Fig. 1. The majority of positive sam-
ples collected at the Belem health centre were lost due to 
a faulty extraction procedure. In order to not introduce 
bias in into the results, it was decided to only go forward 
with samples from Bandim for PCR analysis. All positive 
RDTs collected at the Bandim health centre which were 
received in Denmark (n = 2184, 77% of the RDT posi-
tive samples) were subjected to DNA extraction. Samples 
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that were successfully found logged in the RDT database 
(n = 1879, 86% of the DNA-extracted samples) were then 
checked for PCR-positivity of the ribosomal 18S Plas-
modium subunit. The overall PCR-corrected positivity 
amongst these samples was 74% (n = 1390).
A total of 304 negative RDTs from the 2014 and 2015 
transmission periods, collected at the Bandim health cen-
tre, were also tested for PCR-positivity. Only 1% of these 
(n = 3) were found to be PCR-positive.
PCR success‑rate for single copy genes during library 
preparation
In total, 1390 PCR corrected Plasmodium 18S-positive 
samples were used in nested PCRs designed to amplify 
the various gene fragments analysed in this study. The 
success-rate of single-copy gene PCRs varied from 13 to 
87% (Fig.  1). Specifically, the pfdhfr fragment was suc-
cessfully amplified for 87% of 18S-positive RDTs, while 
pfcrt and pfmdr1 fragment 1 were amplified for 61% and 
56%. The pfmdr1 fragment 2, pfdhps as well as pfk13 
fragments 1–3 were all amplified for 28–36%, and lastly, 
pfk13 fragments 4 and 5 were amplified for 13% and 16%, 
respectively. In total, 5532 gene fragments were success-
fully sequenced.
Molecular markers of anti‑malarial resistance
The observed frequencies of specific haplotypes are 
listed in Table  1 (mixed infections were omitted from 
haplotype analyses), while single SNP frequencies are 
listed in Table 2.
SNPs in pfcrt and pfmdr1
The pfcrt c. 72-76 CVMNK wild type was found to 
decrease significantly through the years of sampling; from 
45/67 (67%) to 187/311 (60%) and to 99/219 (45%) sam-
ples in 2014, 2015 and 2016, respectively (p = 0.006, Fish-
er’s exact test) (Table 1, Fig. 3a). The pfmdr1 c. 86 + 184 
NF haplotype was found in 43/75 (57%), 212/290 (73%) 
and 116/187 (62%) samples, while the NY haplotype was 
found in 22/75 (29%), 68/290 (23%) and 55/187 (29%) 
samples (Table 1, Fig. 3b). SNP frequencies for pfmdr1 c. 
1034, 1042 and 1246 are listed in Table 2.
SNPs in pfdhfr and pfdhps
The pfdhfr c. 51 + 59 + 108 IRN triple mutant was found 
in 60/82 (73%), 373/407 (92%) and 376/443 (85%) samples 
in 2014, 2015 and 2016, respectively (p = 0.001, Table 1, 
Fig.  3c). The pfdhps c. 437G was found in 16/49 (33%), 
105/199 (53%) and 109/185 (58%) samples during 2014, 
2015 and 2016, respectively (mixed infections included). 
Accordingly, the quadruple pfdhfr/pfdhps mutant (pfdhfr 
IRN + pfdhps c. 437G) was found in 33%, 49% and 51% of 
samples. SNP frequencies for pfdhps c. 436, 540, 581 and 
613 are listed in Table 2.
Table 1 Frequencies of  haplotypes found during  the  transmission periods 2014–2016 (May 2014–April 2017), p-values 
are from Fisher’s exact test for trend over time
Mixed infections were omitted from haplotype analysis
Frequencies of haplotypes
Gene Haplotype 2014 2015 2016 p‑value (trend)
18S success 76% (n = 228) 80% (n = 676) 66% (n = 486)
pfcrt
c. 72‑76
CVMNK (wildtype) 67% (45/67) 60% (187/311) 45% (99/219) 0.006
CVIET (mutant) 33% (22/67) 40% (124/311) 55% (120/219) 0.006
pfmdr1
c. 86 + 184
NF 57% (43/75) 73% (212/290) 62% (116/187) 0.052
NY 29% (22/75) 23% (68/290) 29% (55/187) 0.052
YF 11% (8/75) 3% (9/290) 9% (16/187) 0.084
YY 3% (2/75) 0% (1/290) 0% (0/187) 0.109
pfdhfr
c. 51 + 59 + 108
NCS (wildtype) 17% (14/82) 4% (18/407) 4% (17/443) 0.001
IRN (triple mutant) 73% (60/82) 92% (373/407) 85% (376/443) 0.001
pfdhps
c. 436 + 437 + 540 + 581 + 613
AAKAA (wildtype) 25% (17/68) 25% (23/93) 23% (39/170) 0.956
AGKAA (mutant) 15% (10/68) 6% (6/93) 11% (19/170) 0.439
SAKAA (wildtype) 26% (18/68) 29% (27/93) 21% (36/170) 0.083
SGKAA (mutant) 34% (23/68) 38% (35/93) 43% (73/170) 0.448
pfdhfr
c. 51 + 59 + 108 + pfdhps
c. 437
IRN + G (quadruple mutant) 33% (16/49) 49% (97/199) 51% (94/185) 0.072
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SNPs identified in pfk13
As PCR-positivity for Pfk13 fragments was very low, 
only data from the latest of the transmission periods is 
presented. A total of 311 samples collected during the 
2016 transmission period were partially or completely 
sequenced in pfk13, whereof 97 were successfully 
sequenced in the propeller region. In total, 18 SNPs were 
identified in pfk13, only 3 of which were situated in the 
propeller region, 2 of which are non-synonymous (R529K 
and T535M) (Fig. 4). In the N-terminal region, 15 SNPs 
were identified, 12 of which were non-synonymous 
(Fig.  4). None of the identified SNPs occurred in more 
than two samples.
Demographic trends of RDT‑positive versus RDT‑negative 
patients
Sampling was carried out for 36  months, starting May 
2014. Transmission periods were therefore defined as 
periods of 12 months going from May 1 year up to and 
including April the following year, which includes the 
high transmission period September to January. In order 
to compare years and transmission periods, transmission 
Table 2 SNP prevalence, mixed infections counted in both groups
Gene Codon Amino acid 2014 2015 2016
Percentage Count Percentage Count Percentage Count
18S 228 676 486
pfcrt 74 M 74 64 67 267 48 120
I 43 37 53 209 61 152
75 N 74 64 67 267 48 120
E 43 37 53 209 61 152
76 K 74 64 68 271 48 120
T 43 37 53 210 61 152
pfmdr1 86 N 88 70 97 351 92 202
Y 14 11 4 13 13 29
184 F 70 56 81 315 74 163
Y 34 27 42 163 38 84
1034 S 100 67 100 182 100 202
C 0 0 0 0 0 0
1042 N 100 67 100 182 100 202
D 0 0 0 0 0 0
1246 D 96 64 100 182 100 201
Y 4 3 0 0 0 1
pfdhfr 51 N 28 24 9 40 16 80
I 76 65 94 408 92 471
59 C 29 25 11 47 19 96
R 76 65 93 403 91 466
108 S 20 17 7 35 7 40
N 84 73 96 449 97 526
164 I 100 86 100 432 100 513
L 0 0 0 0 0 0
pfdhps 436 S 73 36 77 157 68 127
A 31 15 30 62 36 67
437 A 67 33 57 114 47 88
G 33 16 53 107 58 109
540 K 98 52 99 134 99 186
E 2 1 1 2 1 2
581 A 100 53 100 136 100 185
G 0 0 0 0 0 0
613 A 100 52 98 129 99 187
S/T 0 0 2 2 1 1
Page 8 of 13Nag et al. Malar J          (2019) 18:252 
periods have been named according to the year when 
transmission started. The number of positive RDTs col-
lected during the 2014, 2015 and 2016 transmission peri-
ods were 497, 1374 and 961, respectively (Fig.  5a). The 
number of positive RDTs collected during the 2014 trans-
mission period was substantially lower than the numbers 
collected in the two later transmission periods. Unex-
pected “dips” in the number of RDT positive patients 
were seen during January and September 2016 (Fig. 5a).
The median age of patients with a positive RDT was 
19  years (interquartile range (IQR) 11–28) (Fig.  5b). 
When divided into age groups of < 5 years, 5–9, 10–14 
and ≥ 15, the number of patients with positive RDTs 
were 190 (6%), 327 (12%), 428 (15%) [children less than 
15 years of age combined = 945 (34%)] and 1847 (66%) 
(Fig.  5c, 40 samples did not have age stated). The sex 
distribution amongst RDT positive patients was 1145 
a b
dc
Fig. 3 Molecular markers of anti‑malarial resistance 2014–2017. a Frequency of pfcrt c. 72‑76 haplotypes CVMNK and CVIET found each 
consecutive transmission season. b Frequency of pfmdr1 c.86 + 184 haplotypes NF, NY, YF and YY found each consecutive year. c Frequency of 
pfdhfr c. 51 + 59 + 108 haplotypes IRN, NCS and “other” (consisting of NCN, ICN and NRN) found each consecutive year. The single mutant NCN 
represented 6/8 “other” pfdhfr haplotypes during the 2014 transmission season, while the two double mutants ICN and NRN combined accounted 
for 15/16 and 49/50 of “other” pfdhfr haplotypes found during the 2015 and 2016 transmission seasons, respectively. d Frequency of pfdhps c. 
436 + 437 + 540 + 581 + 613 haplotypes AAKAA, AGKAA, SAKAA and SGKAA found each consecutive year
Fig. 4 pfk13 polymorphisms observed 2016–2017. Polymorphisms detected in pfk13 during the transmission season from September 2016–
January 2017. The grey bar indicates the N‑terminal part of the translated K13 protein, while the coloured bars (yellow, blue, brown, peach, green 
and purple) indicate blades 1–6 in the propeller region. Grey circles indicate a synonymous SNP, while black circles indicate a non‑synonymous SNP. 
Positions refer to amino‑acid positions in the translated protein. The R529K and T535M mutations were each found only once
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males (52%) and 1647 females (48%) (Fig.  5d, 40 sam-
ples did not have sex stated).
The total number of negative RDTs collected was 
12,101. The number of negative RDTs collected during 
the 2014, 2015 and 2016 transmission periods were 4001, 
4362 and 3738 (RDT negative database only includes 
until February 19th 2017), respectively. The median age of 
patients with a negative RDT was 18 years (IQR = 4–30) 
(Fig. 5b). When divided into age groups of < 5 years, 5–9, 
10–14 and ≥ 15, the number of patients with a negative 
RDT was 3154 (26%), 1503 (13%), 721 (6%) and 6638 
(55%) (Fig. 5c, 85 samples did not have age stated). The 
sex distribution amongst RDT negative patients was 6248 
males (52%) and 5768 females (48%) (Fig. 5d, 85 samples 
did not have gender stated).
In order to assess whether the proportion of adults was 
higher in the group of RDT positive patients than in the 
general population, proportions were compared to that of 
the general population of the country, estimated in 2015 
as 41.7% children below the age of 15 vs 58.3% adults 
[26]. The proportion of adults within the group of RDT-
positive patients was found to be significantly higher than 
that within the general population (Pearsons Chi square, 
p = 0.05), while the proportion of adults within the entire 
group of RDT-tested patients was not.
Discussion
Proof of concept
Applicability of the used RDTs for the molecular analyses
The study found that only 74% of the positive RDTs 
collected contain PCR-detectable Plasmodium DNA, 
which is required for molecular surveillance. This find-
ing illustrates that the cost-efficiency of using RDTs 
for molecular surveillance is substantially affected by 
pre-screening the samples for the presence of Plas-
modium DNA, as a notable percentage of samples is 
proven inapplicable for library preparation at this stage. 
Furthermore, the PCR-positivity of the single-copy 
genes involved in conferring resistance towards anti-
malarial drugs varied tremendously from 13 to 87% 
after corrected 18S PCR-positivity. Let it be noted that 
the applied PCR protocols have been extensively opti-
mized (see methods section) to increase positivity rates 
on RDT extracts. Studies using erythrocyte-enhanced 
a b
dc
Fig. 5 Description of RDT positive and negative patients included in the study. a Number of positive RDTs collected at the two health centres 
combined every month, for the three consecutive years of sampling, going from May to April. The malaria transmission season goes from 
September through January. b Median age and IQR of RDT positive and RDT negative patients included throughout the study. c Age distribution of 
RDT positive and RDT negative patients into groups consisting of < 5 years, 5–9 years, 10–14 years and ≥ 15 years. d Sex distribution of RDT positive 
and RDT negative patients throughout the study
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samples [15] or dried venous blood spots (not eryth-
rocyte-enhanced) on filter paper (Schmiegelow, Hans-
son, Nag and Alifrangis, unpublished) subjected to the 
same protocol resulted in PCR positivity of at least 90% 
for all fragments. Both the minute amount of parasite 
DNA available from an RDT, the DNA extraction pro-
tocol applied, as well as the state of the DNA in ques-
tion (both at the time of extraction and at the time of 
running PCRs) may have contributed to the consider-
able variation in PCR positivity of single-copy genes. 
Unfortunately, the storage conditions and consequent 
degradation of DNA in used RDTs sampled at local 
health facilities, will be difficult to optimize in compari-
son to the protocols applied. However, a preliminary 
screening of the DNA extracts for parasitaemia/relative 
amount of parasite DNA available from the extracts, 
could allow for implementation of a minimum-value 
necessary for justification of library preparation from 
individual samples. While such an approach requires 
adding an extra qPCR step to the overall analysis, this 
qPCR step could actually replace the initial 18S screen-
ing step by providing information regarding to whether 
or not extracts contain parasite DNA, as well as indi-
cate the relative amounts when doing so.
Overall, the analysis became more expensive per sam-
ple when using RDTs, than it would have been if sam-
ples had consisted of dried venous blood. This is due to 
several facts (1) library preparation consisted of simplex 
nested PCRs rather than multiplex non-nested PCRs, (2) 
primer concentrations applied were higher, (3) PCR pro-
grams were longer (machines ran for longer time) and (4) 
a considerable amount of samples were used for library 
preparation resulting in little to no data output. It was, 
however, still feasible to sequence 5532 gene fragments of 
approximately 500  bp, all with individual indices allow-
ing trace-back to the sample of origin, on a single Miseq 
V3 flow cell with paired-end reads. With an approxi-
mate price for a Miseq V3 flow cell of USD 2300, this 
amounts to a sequencing cost per amplicon sequenced 
of USD 0.42. These costs do not include resources used 
during DNA extractions and PCR procedures, however 
they also do not reflect the resources saved from using 
spent RDTs rather than sampling venous blood spots. 
This study undoubtedly illustrates that many resources 
are used extracting DNA and running PCRs from sam-
ples that eventually will not result in any data output, 
illustrating that RDTs are not a perfect match for an NGS 
platform like the one described. However, due to the con-
venience and affordability in acquiring spent RDTs as 
well as the possibility of simultaneously and efficiently 
analysing a very large number of samples on a single 
flow cell through custom indexing, this study also illus-
trates that despite a massive loss in potential data output, 
combining RDTs with NGS still proves relatively afford-
able and efficient.
Other noteworthy limitations to using RDTs as illus-
trated by the current study, include the fact that routine 
sampling of RDTs is completely dependent on RDT avail-
ability. In our study, RDTs may have been out of stock 
during January and September 2016, where unexplained 
“dips” in malaria frequency are seen for periods of time, 
in which case inclusion numbers for these months would 
be biased. Furthermore, the nested PCR protocol which 
is required for the DNA extracted from RDTs, poses a 
much larger contamination risk during PCR procedures, 
than a non-nested PCR protocol [27, 28]. Finally, there 
are no sample backups when sampling RDTs, which may 
become a logistical and ethical concern, as samples can 
rather easily be completely lost until DNA is successfully 
extracted and backups created.
Molecular markers of anti‑malarial resistance
The high prevalence of pfmdr1 86N in the current study, 
resembles previously published data for the same study 
area in 2010–2012 (approximately 80%) [29], indicating 
a relatively stable prevalence. The data corresponds well 
with the use of AL and the AL-derived selection of the 
pfmdr1 c. 86N [30–32]. Importantly however, a recently 
performed efficacy study indicates that the efficacy of 
AL is still 94–95% [20], indicating that the prevalence of 
the pfmdr1 c. 86N at levels between 88 and 97% is not 
affecting AL treatment efficacy in this setting. AL (lume-
fantrine specifically) has also been shown to select for 
the pfcrt 76K wildtype [33]. However, the study found 
a significant increase of the mutant pfcrt CVIET haplo-
type over the study period. A similar trend has previously 
been observed in the same study area and QN usage was 
speculated to be the cause [29, 34]. QN is typically used 
at a suboptimal dosage (10 mg/kg × 2 for 3 days) in Bis-
sau, and its effectiveness is < 50%. However, it may also 
be that the two observed events (2010–2012 and 2014–
2016) of increasing levels of the CVIET haplotype rep-
resent “highs” in a more long-term fluctuation of this 
haplotype.
The levels of the pfdhfr IRN triple mutant found in this 
study (fluctuating between 73 and 92%) indicate selection 
of this haplotype since earlier studies were conducted 
(in 2004; prevalence of 41%) [35]. Likewise, the current 
levels of the pfdhfr/pfdhps quadruple mutant (33–51%) 
indicate selection since previous studies were conducted 
(15% quadruple mutant in 2004) [35]. Large scale use of 
IPTp may have contributed to this selection, since IPTp 
is the only SP-based treatment that is still recommended 
and implemented in Guinea-Bissau [19], apart from a 
very recent deployment of seasonal malaria chemopre-
vention (SMC by use of SP + amodiaquine) in a northern 
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region of the country [36]. SP was never first-line treat-
ment in Guinea-Bissau, but was recommended as sec-
ond-line treatment from 1996 to 2007. Selection may 
also be caused by use of SP for self-treatment of malaria, 
the use of sulfamethoxazole–trimethoprim for bacte-
rial infections, and finally it is also possible that quadru-
ple mutants are imported from neighbouring countries 
where SP has been used as first-line treatment and where 
mutant haplotypes have historically been more prevalent 
than in Guinea-Bissau [37–39].
Importantly, the current study revealed no SNPs of 
concern in pfk13 [40]. Combined with the previously 
published data regarding pfk13 polymorphisms from the 
area [15], there are no signs of artemisinin selective pres-
sure of the kind seen in South-East Asia and Suriname 
[3].
False positivity and false negativity of RDTs—
epidemiological insights
Approximately 74% of the positive RDTs were found 
PCR positive for the multicopy Plasmodium 18S subunit, 
indicating a diagnostic false positivity percentage of 26%. 
Patients may very well have had circulating antigens, and 
hence the test was not false to be positive, but with no 
circulating parasites the patient did not actually have 
malaria, in contrary to the diagnosis. There is of course 
a limit of detection that applies to the 18S PCR, as well 
as the possibility of DNA degradation over time. How-
ever, with the typical detection limit of RDTs of 100–200 
parasites/µl, a false positivity rate of 26% is not surpris-
ing. Furthermore, the current study found only 1% of 
the tested negative RDTs to be PCR positive, and hence 
false negative. The limit of detection of the 18S PCR, as 
well as the possibility of DNA degradation also apply to 
this finding. The low percentage of false negative RDTs, 
however, is not surprising given the setting of the study: 
included patients all referred to the clinic with symptoms 
and children were included in the study. Previous studies 
on the current epidemiology of malaria in the area have 
found that there is a decrease in acquired immunity, and 
that even older adolescents react with symptoms. Lastly, 
recent surveys have shown a decreasing prevalence, and a 
high percentage of sub-patent infections were, therefore, 
not expected.
Demographic trends
The demographic data obtained from routinely collect-
ing used RDTs, indicate that there was less malaria dur-
ing the 2014 transmission period, than during 2015 and 
2016 transmission periods. According to rainfall data 
obtained from Bandim for the three seasons, an increase 
in rainfall from 2014 to 2015 was observed, which may 
have contributed to a rise in malaria cases (yearly rainfall 
was 941.2 mm in 2014, 1393 mm in 2015 and 983.9 mm 
in 2016) [41]. A country-wide long-lasting insecticide-
treated bed net distribution campaign and subsequent 
follow-up study carried out in June and December 2014, 
confirmed the low prevalence in 2014 (1.3% amongst 
children aged 0–59  months and 0.7% amongst children 
5–14  years) [42]. Furthermore, according to the inclu-
sion data from our study, adults (patients ≥ 15  years) 
represent the majority of infections during transmission 
periods, with a significantly larger proportion of adults 
amongst RDT positive patients, than amongst the entire 
RDT-tested population and the general population of the 
country [26]. These findings correspond well with the 
trend of increasing median age of malaria patients previ-
ously described for the study area [17, 18].
Conclusion
This study provides proof of concept for the use of RDTs 
for molecular surveillance of anti-malarial resistance 
through massively parallel amplicon sequencing with 
Illumina technology, while highlighting major challenges 
when doing so. Furthermore, the study provides evidence 
that there is a high frequency of the pfmdr1 c. 86N, that 
the pfcrt CVIET haplotype has increased significantly 
over the course of the study, that the pfdhfr/pfdhps quad-
ruple mutant has increased substantially in frequency 
since 2004, and that there are no accumulating SNPs in 
pfK13 as of May 2017 in Bissau, Guinea-Bissau. Lastly, 
the study provides evidence as to how routine sampling 
of used RDTs combined with minimal patient data, can 
provide insight regarding basic demographic trends 
amongst the malaria patients.
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